GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹1,608 Cr | ₹1,565 Cr | ₹1,398 Cr | ₹729 Cr | ₹582 Cr |
What is the latest Total Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹1,608 Cr |
| Mar2025 | ₹1,565 Cr |
| Mar2024 | ₹1,398 Cr |
| Mar2023 | ₹729 Cr |
| Mar2022 | ₹582 Cr |
How is Total Current Liabilities of GLAND PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,608 Cr | 2.78 | |
| Mar2025 | ₹1,565 Cr | 11.91 | |
| Mar2024 | ₹1,398 Cr | 91.78 | |
| Mar2023 | ₹729 Cr | 25.28 | |
| Mar2022 | ₹582 Cr | - | |
Compare Total Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹54,302.3 Cr | -1.3% | 12.5% | 76.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,228.0 Cr | 1.2% | 9.1% | 6.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹296,741.0 Cr | -2.7% | 22.2% | 70% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,413.0 Cr | -1% | 2% | 20.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹116,771.0 Cr | 1.5% | 13% | 12.1% | Stock Analytics | |
| CIPLA | ₹114,397.0 Cr | 1.7% | 7.8% | -7.3% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -1.3% |
12.5% |
76.4% |
| SENSEX | 1.4% |
12.4% |
-1.7% |
You may also like the below Video Courses